Abstract:Natural compounds are becoming popular for the treatment of illnesses and health promotion, but the mechanisms of action and safety profiles are often unknown. Xyloketal B (XKB) is a novel marine compound isolated from the mangrove fungus Xylaria sp., with potent antioxidative, neuroprotective, and cardioprotective effects. However, its molecular targets and effects on drug-metabolizing enzymes are unknown. This study aimed to investigate the potential molecular targets of XKB using bioinformatic approaches and to examine the effect of XKB on the expression and activity of rat cytochrome P450 3a (Cyp3a) subfamily members using midazolam as a model probe. DDI-CPI, a server that can predict drug-drug interactions via the chemical-protein interactome, was employed to predict the targets of XKB, and the Database for Annotation, Visualization and Integrated Discovery (DAVID) was used to analyze the pathways of the predicted targets of XKB. Homology modeling was performed using the Discovery Studio program 3.1. The activity and expression of rat hepatic Cyp3a were examined after the rats were treated with XKB at 7 and 14 mg/kg for 8 consecutive days. Rat plasma concentrations of midazolam and its metabolite 1'-OH-midazolam were determined using a validated high-performance liquid chromatographic method. Bioinformatic analysis showed that there were over 324 functional proteins and 61 related signaling pathways that were potentially regulated by XKB. A molecular docking study showed that XKB bound to the active site of human cytochrome P450 3A4 and rat Cyp3a2 homology model via the formation of hydrogen bonds. The in vivo study showed that oral administration of XKB at 14 mg/kg to rats for 8 days significantly increased the area under the plasma concentration-time curve (AUC) of midazolam, with a concomitant decrease in the plasma clearance and AUC ratio of 1'-OH-midazolam over midazolam. Further, oral administration of 14 mg/kg XKB for 8 days markedly reduced the activity and expression of hepatic Cyp3a in rats. Taken together, the results show that XKB could regulate networks of molecular proteins and related signaling pathways and that XKB downregulated hepatic Cyp3a in rats. XKB might cause drug interactions through modulation of the activity and expression of Cyp3a members. More studies are warranted to confirm the mechanisms of action of XKB and to investigate the underlying mechanism for the regulating effect of XKB on Cyp3a subfamily members.

A Novel Marine Compound Xyloketal B Protects Against Oxidized LDL-induced Cell Injury in Vitro.

Marine compound Xyloketal B protects PC12 cells against OGD-induced cell damage

Xyloketal B: A marine compound with medicinal potential

Xyloketal B Attenuates Atherosclerotic Plaque Formation And Endothelial Dysfunction In Apolipoprotein E Deficient Mice

Xyloketal B Exhibits Its Antioxidant Activity Through Induction Of Ho-1 In Vascular Endothelial Cells And Zebrafish

Xyloketal B alleviates cerebral infarction and neurologic deficits in a mouse stroke model by suppressing the ROS/TLR4/NF-κB inflammatory signaling pathway

Protective effects of xyloketal B against MPP+-induced neurotoxicity in Caenorhabditis elegans and PC12 cells.

Xyloketal B Exerts Antihypertensive Effect in Renovascular Hypertensive Rats Via the NO-sGC-cGMP Pathway and Calcium Signaling

Xyloketal B Reverses Nutritional Hepatic Steatosis, Steatohepatitis, and Liver Fibrosis through Activation of the PPAR alpha/PGC1 alpha Signaling Pathway

Xyloketal B Reverses Nutritional Hepatic Steatosis, Steatohepatitis, and Liver Fibrosis Through Activation of the PPARα/PGC1α Signaling Pathway.

Xyloketal B Alleviates Cerebral Infarction and Neurologic Deficits in Mouse Middle Cerebral Artery Occlusion Model

Design, synthesis and biological evaluation of marine phidianidine-inspired derivatives against oxidized ldl-induced endothelial injury by activating Nrf2 anti-oxidation pathway

Effects of marine compound xyloketal B on neuroprotection and potential drug development

Xyloketal B, a Marine Compound, Acts on a Network of Molecular Proteins and Regulates the Activity and Expression of Rat Cytochrome P450 3a: a Bioinformatic and Animal Study.

Bixin, a New Atheroprotective Carotenoid Candidate, Prevents oxLDL-Induced Cytotoxicity and Mitochondrial Dysfunction in Macrophages: Involvement of the Nrf2 and NF-κB Pathways

XJP-1 Protects Endothelial Cells from Oxidized Low-Density Lipoprotein-Induced Apoptosis by Inhibiting NADPH Oxidase Subunit Expression and Modulating the PI3K/Akt/eNOS Pathway

Protective effects of a compound herbal extract (Tong Xin Luo) on free fatty acid induced endothelial injury: Implications of antioxidant system

Synthesis and Neuroprotective Action of Xyloketal Derivatives in Parkinson’s Disease Models

The novel anthraquinone compound Kanglexin prevents endothelial-to-mesenchymal transition in atherosclerosis by activating FGFR1 and suppressing integrin β1/TGFβ signaling

Synthesis And Neuroprotective Action Of Xyloketal Derivatives In Parkinson'S Disease Models

Ginsenoside compound K protects human umbilical vein endothelial cells against oxidized low-density lipoprotein-induced injury via inhibition of nuclear factor-κB, p38, and JNK MAPK pathways